Using Inside-Out Open Innovation to Recover Abandoned Pharmaceutical Compounds
Pharmaceutical drug development costs have risen rapidly over the past twenty years. However, the number of new molecular entities being approved has not increased. As pharmaceutical companies scale back their R&D in light of this deteriorating productivity, significant unmet medical needs rem...
Main Authors: | Henry Chesbrough, Eric L. Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Universidade do Porto, Faculdade de Engenharia (FEUP)
2015-07-01
|
Series: | Journal of Innovation Management |
Subjects: | |
Online Access: | https://journalsojs3.fe.up.pt/index.php/jim/article/view/280 |
Similar Items
-
Factors Affecting the Outbound Open Innovation Strategies in Pharmaceutical Industry: Focus on Out-Licensing Deal
by: Insoo Lee, et al.
Published: (2019-09-01) -
New Progression of Open Innovation in the Pharmaceutical Industry: Open on the Sales Process of Japanese Pharmaceutical Companies
by: Takahisa YAMAZAKI
Published: (2025-02-01) -
The Moderating Effects of Dynamic Capability on Radical Innovation and Incremental Innovation Teams in the Global Pharmaceutical Biotechnology Industry
by: Heather Johnson
Published: (2020-04-01) -
Innovation in Pharmaceutical Assistance
by: Jean Leandro Dos Santos
Published: (2022-07-01) -
Inbound and Outbound Open Innovation: Organization and Performances
by: Francesca Michelino, et al.
Published: (2014-09-01)